Loading clinical trials...

UNKNOWNNA

HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation

A Safety and Efficacy Study of Autologous Bone Marrow Cell Infusion Therapy in HIV Infected Patients With Advanced Liver Cirrhosis

NCT01309594•National Center for Global Health and Medicine, Japan

View on ClinicalTrials.gov

Summary

An international investigation to evaluate if, and if so how long, autologous bone marrow hematopoietic stem cell transplantation can safely restore liver functions for HIV infected patients who have decompensated liver cirrhosis.

Detailed Description

An international investigation to evaluate if, and if so how long, autologous bone marrow (ABM) hematopoietic stem cell transplantation (HSCT) can safely restore liver functions for HIV infected patients who have decompensated liver cirrhosis.

Eligibility

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•have cirrhosis with 7 or higher Child-Pugh Score in Child-Pugh Score B
•able to consent and willing to participate in the study
•under good control for HIV infection

Exclusion Criteria

•Hepatocellular carcinoma (HCC), except for cases having been completely treated without history of recurrence
•Malignant tumors other than HCC
•Alcoholic liver disease (ALD)
•Hemoglobin under 8g/dL or Platelets under 20/ml at the registration
•Esophageal or gastric varices with a risk of bursting, except for cases with only cured history of such conditions
•Cases that cannot obtain the informed consent to autologous blood transfusion
•Pregnancy
•Renal dysfunction with 2mg/dL or higher serum creatinine
•Performance Status 3 or 4 (assessment excludes hemophilic arthritis related daily life limitations)
•Cases not fit for general anesthesia
+1 more criteria

Locations (1)

National Center for Global Health and Medicine

Shinjuku, Tokyo, Japan

Key Dates

Start Date

March 1, 2011

Primary Completion Date

March 1, 2016

Completion Date

March 1, 2016

Last Updated

September 25, 2014

Enrollment

ESTIMATED participants

Conditions

HIV InfectionAIDSCirrhosis

Interventions

Hematopoietic stem cell transplantation

PROCEDURE

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITINGNA

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

NCT05597488

Cirrhosis Portal

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation

Inclusion Criteria

Exclusion Criteria

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias